FDA AVANDIA Hearing – Day Two update

The officials voting today were presented with multiple choice questions. Question three had a choice of

A. The data provides sufficient evidence to raise significant safety concerns in diabetes type 2 patients taking Rosiglitazone (Avandia).

B. The data does not provide sufficient evidence to raise significant safety concerns in diabetes type 2 patients taking Avandia.

C. There is not enough evidence to make a decision.

The answers to this question resulted in the doctors choosing

A. 21
B. 4
C. 8

This is a good result for patients taking Avandia who have experienced grave morbid effects because the officials voting are all well trained and educated professionals. We hope that yesterday’s and today’s hearing will provide the FDA enough proof and support to make a decision to pull Avandia off the market.